ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
5 hedge funds and large institutions have $120K invested in ELITE PHARMACEUTICAL in 2015 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
9% more capital invested
Capital invested by funds: $110K → $120K (+$10.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRM
Westport Resources Management
Westport,
Connecticut
|
+$1K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GA
1
Geneva Advisors
Chicago,
Illinois
| $71K | – | – | – |
|
2
Ameriprise
Minneapolis,
Minnesota
| $18K | – | – | – |
|
|
GIA
3
Guyasuta Investment Advisors
Pittsburgh,
Pennsylvania
| $15K | – | – | – |
|
|
JAFL
4
Jay A. Fishman Ltd
Troy,
Michigan
| $14.7K | – | – | – |
|
|
WRM
5
Westport Resources Management
Westport,
Connecticut
| $1K | +$1K | +2,500 | New |
|
ELI Hedge Fund Activity: Q1 2015 in Review
5 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2015, worth a combined $120K — up 9.3% from $110K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Westport Resources Management, opening a new position worth an estimated $1K.
- 5 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2015, up from 4 in Q4 2014.
- Funds reported $120K of ELITE PHARMACEUTICAL stock for Q1 2015, up 9.3% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q1 2015 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q1 2015 was Westport Resources Management, an estimated $1K added.
Based on aggregated 13F filings for Q1 2015.